How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol Transport

Antioxidants, Journal Year: 2025, Volume and Issue: 14(4), P. 430 - 430

Published: April 2, 2025

Low-density lipoprotein (LDL) chemically modified by reactive oxygen species (ROS), for example, leaking from red blood cells in the vascular compartment, more readily crosses endothelium than does nonoxidatively LDL to enter tissue fluid. Oxidatively (oxLDL) may also be created fluid ROS design, inflammatory white cells, or simply other as a consequence of metabolism. As well oxLDL, glycatively (glycLDL) is formed circulation. High-density (HDL) appears capable decreasing burden lipid peroxides on exposed glucose and its metabolites. The mechanism this that has received most attention antioxidant activity HDL, which due large part presence paraoxonase 1 (PON1). PON1 intimately associated with apolipoprotein A1 component HDL’s domains into cell membranes can transferred. It frequently overlooked hydrolyze substrates, it essential remain virtue hydrophobic amino acid sequences within micellar environment, during isolation serum genetically culture. Otherwise, retain capacity water-soluble such phenyl acetate, whilst failing lipid-soluble molecules. OxLDL probably glycLDL, once they have crossed arterial receptor-mediated transcytosis, are rapidly taken up monocytes process involves scavenger receptors, leading subendothelial foam formation. These precursors atheroma, inducing cross lesion proliferation migration myocytes present wall developing lesion, where transform fibroblasts. atheroma progresses central extracellular lake cholesteryl ester following necrosis apoptosis an overlying fibrous cap continuing grow concentrically around involving oxLDL glycLDL. Within wall, additional generated secreted leakage generally when couplet reduced. important HDL opposes atherogenesis, provide better avenue inquiry identification vulnerable individuals provision new therapies emerged emphasis placed role RCT.

Language: Английский

Relation between bone mineral density and oxidative stress in Egyptian patients with chronic kidney disease: a cross sectional study

BMC Nephrology, Journal Year: 2025, Volume and Issue: 26(1)

Published: April 18, 2025

Abstract Background Chronic kidney disease (CKD) patients are prone to osteoporosis (OP) and they had significant oxidative stress. The relationship between stress (OS) bone mineral density (BMD) in CKD is not entirely clear. investigation of this relation pronounced importance decreasing the occurrence among cases. Objectives To evaluate association BMD OS patients. Methods We performed a case-control study, including 150 adults with (stage 1–5 according Kidney Disease Improving Global Outcomes (KDIGO) classification, 2024) healthy controls. were further subdivided 3 subgroups based on estimated glomerular filtration rate: stage 1–2, 3–4 5. at lumbar spine (LS), femur neck (FN), distal radius (DR) measured using DEXA. Vitamin D biomarkers including; 8-Hydroxy-2’-deoxyguanosine (8-OHdG) Malondialdehyde (MDA) measured. Paraoxonase1 (PON1) as biomarker antioxidant response was assessed. Statistical analysis appropriate tests. Results cases showed lower T-Scores than Moreover, LS, DR, FN BMDs significantly different stages. Post hoc analyses higher Stage I-II vs. III-IV V. However, no differences noted V for all sites. Significant increase (8-OHdG MDA) while activity (PON-1) severity observed. There positive correlation PON1and 8-OHdG MDA negative BMD. also observed correlations alkaline phosphatase phosphorus, these markers vitamin calcium. PON1 & Conclusion suffer OS. positively correlated severity. CKD. might participate OP

Language: Английский

Protective Role of Royal Jelly on the Growth of the MCF-10A Cell Line Treated with Cisplatin

International Journal of Cancer Management, Journal Year: 2025, Volume and Issue: 18(1)

Published: May 6, 2025

Background: Royal jelly (RJ) possesses numerous beneficial properties. When used in conjunction with pharmacological agents, it may enhance the inhibition of tumor growth and help manage side effects induced by drugs. Objectives: The present study aimed to examine simultaneous RJ cisplatin on rate normal breast cells. Methods: MCF-10A cell line (CRL-10317) was obtained from Avicenna Research Institute bank Iran. Following culture (at 37℃ an incubator 5% Co2), cells were treated serial concentrations RJ, ranging 0 5 - 10 20 30 40 50 75 100 250 μg/mL 500 μg/mL, respectively, for durations 24, 48, 72 hours. Cell viability assessed using MTT assay, one-way ANOVA post-hoc tests (LSD Tukey) statistical analysis. protocol approved Ethics Committee Islamic Azad University, Tehran Medical Branch (IR.IAU.PS.REC.1401.138). Results: Cisplatin alone reduced across all time points (P < 0.0001). at above increased after 48 hours = 0.00217) Combined treatment initially decreased 0.0001), but higher stabilized hours, suggesting a protective effect. Conclusions: demonstrates role against cisplatin-induced toxicity cells, potentially preserving healthy tissue during chemotherapy. These findings, while promising adjunctive therapies, require further validation diverse lines clinical settings confirm generalizability.

Language: Английский